Portal de Periódicos da CAPES

5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation

2009; Springer Nature; Volume: 45; Issue: 2 Linguagem: Inglês

10.1038/bmt.2009.134

1476-5365

Teresa Field, Janelle Perkins, Yifan Huang, Mohamed A. Kharfan‐Dabaja, Melissa Alsina, Ernesto Ayala, Hugo F. Fernández, William E. Janssen, Jeffrey E. Lancet, Lia Perez, Daniel M. Sullivan, Alan F. List, Claudio Anasetti,

Multiple Myeloma Research and Treatments

Relapse remains a leading cause for treatment failure after hematopoietic cell transplantation (HCT) in patients with intermediate- or high-risk myelodysplastic syndrome (MDS). To discern the impact of 5-azacitine treatment pretransplant on the risk for relapse after HCT, we analyzed the post transplant outcomes of all 54 consecutive patients with MDS or chronic myelomonocytic leukemia who received HCT from HLA-compatible donors according to pretransplant 5-azacitidine exposure. Thirty patients received a median of four (1-7) cycles of 5-azacitidine, and 24 patients did not receive 5-azacitidine before HCT. The 1-year estimates of overall survival, relapse-free survival and cumulative incidence of relapse were 47, 41 and 20%, for 5-azacitidine patients and 60, 51 and 32%, respectively, for non-5-azacytidine patients. These observations suggest that outcomes are similar in both groups with a trend toward decreased early relapse in patients receiving 5-azacitidine. 5-Azacitidine may be of value in stabilizing the disease, thereby allowing time for patients to reach transplant and does not appear to affect transplant outcomes.